NCT06190678View on ClinicalTrials.gov

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
HealthyRenal Insufficiency
Interventions
DRUG

Pirtobrutinib

Administered orally

Trial Locations (5)

32132

Riverside Clinical Research, Edgewater

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

55114

Prism Research, Saint Paul

92801

Orange County Research Institute, Anaheim

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06190678 - Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants | Biotech Hunter | Biotech Hunter